Robert Rosiello named chief financial officer of Valeant

Quebec, Canada-based drug company Valeant Pharmaceuticals International (NYSE: VRX) has appointed Robert Rosiello as chief financial officer.

He joins from multinational consulting firm McKinsey & Company, where he spent 10 years as a senior partner in charge of the global merger practice. He led M&A integrations for pharma, specialty pharma and medical device companies in the USA, Europe and Asia.

Michael Pearson, chairman and chief executive of Valeant, said: "Rob is someone I have worked closely with for 20 years.  I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders. I want to thank Howard for his strong leadership to both myself and the entire organization these past few years and I will continue to rely on his valuable counsel as a member of our board of directors."